Filed by Nuvelo, Inc. Pursuant to Rule 425
Under the Securities Act of 1933
And Deemed Filed Pursuant to Rule 14a-12
Under the Securities Exchange Act of 1934
Subject Company: ARCA biopharma, Inc.
Commission File No. 333-154839
|
|
|
|
|
|
|
|
|
Contact:
|
|
|
Danielle Bertrand
WeissComm Partners
415-946-1056
dbertrand@wcpglobal.com
|
|
Greg Gin
Invigorate Communications
908-376-7737
ggin@invigoratepr.com
|
NUVELO AND ARCA BIOPHARMA ADVANCE TOWARD
COMPLETION OF MERGER
Nuvelo
Stockholder Meeting Scheduled for January 7, 2009
San Carlos, California and Broomfield, Colorado, December 1,
2008
Nuvelo, Inc. (Nasdaq: NUVO) and ARCA biopharma, Inc., a privately-held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced that a special meeting of
Nuvelos stockholders will take place on Wednesday, January 7 at 9 a.m. PT at Nuvelos headquarters at 201 Industrial Road, San Carlos, CA, 94070. The purpose of the special meeting is, among other matters, to approve the actions
necessary to consummate the merger between the two companies announced on September 25, 2008.
Under the terms of the merger
agreement, ARCA will become a wholly owned subsidiary of Nuvelo. Nuvelo will issue new shares of its common stock to ARCA common and preferred stockholders and assume outstanding ARCA options and warrants. When the merger closes, ARCA equity holders
are expected to own or have the right to acquire approximately 67 percent of the common stock of the combined company on a fully-diluted basis. Current Nuvelo stockholders are expected to own approximately 33 percent of the common stock of the
combined company on a fully-diluted basis. The board of directors of the combined company is expected to have seven representatives from the current ARCA board, and three representatives from the current Nuvelo board. The chief executive officer of
the combined company is expected to be Richard B. Brewer, the chief executive officer of ARCA. After the merger occurs, the name of the combined company is expected to be changed to ARCA biopharma, Inc.
At the special meeting, the Nuvelo stockholders will be asked to approve the issuance of Nuvelo common stock to ARCA equity holders, and to approve
amendments to Nuvelos amended and restated certificate of incorporation to effect a reverse stock split and to increase the number of authorized shares of Nuvelo common stock, among other matters.
The board of directors of Nuvelo has fixed November 11, 2008 as the record date for the determination of stockholders entitled to notice of, and to
vote at, the special meeting.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelos
development pipeline includes NU172, a direct thrombin inhibitor which has completed Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator in Phase 1
development for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway
therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is
available at its website at http://www.nuvelo.com or by phoning 650-517-8000.
About ARCA biopharma
ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other
cardiovascular diseases. The Companys lead product candidate, Gencaro(TM) (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications.
ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro. The New Drug Application for approval of Gencaro for the indication of chronic heart failure, including the proposed brand name, is
currently under review by the U.S. Food and Drug Administration. The companion genetic test for Gencaro is in development by ARCAs partner, Laboratory Corporation of America. For more information please visit http://www.arcabiopharma.com.
Forward-looking statements
This press
release contains forward-looking statements which include, without limitation, statements regarding the completion of the proposed merger transaction between Nuvelo, ARCA and Dawn Acquisition Sub, Inc., the transactions anticipated
timing, progress and anticipated completion of the combined companys clinical stage and research programs, which statements are hereby identified as forward-looking statements for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. Such statements are based on the companies managements current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including, without limitation, failure of Nuvelo or ARCAs stockholders to approve the merger, the ability to complete the transaction contemplated by this communication in a timely
fashion, the risk that Nuvelos and ARCAs business operations will not be integrated successfully; the combined companys inability to further identify, develop and achieve commercial success for products and technologies; the risk
that the combined companys financial resources will be insufficient to meet the combined companys business objectives; uncertainties relating to drug discovery and the regulatory approval process; clinical development processes;
enrollment rates for patients in the companies clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact
of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelos filings with the SEC, including without limitation Nuvelos quarterly report on Form 10-Q for the quarter
ended September 30, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
Additional Information and Where to Find It
Nuvelo has filed a registration statement on Form S-4, and a related proxy statement/prospectus/consent solicitation, in connection with the merger.
Investors and security holders are urged to read the registration statement on Form S-4 and the related proxy statement/prospectus/consent solicitation because they contain important information about the merger transaction. Investors and security
holders may obtain free copies of these documents and other documents filed with the SEC at the SECs website at http://www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by
contacting Nuvelo Investor Relations at the email address: ir@nuvelo.com or by phone at 650-517-8000.
In addition to the registration
statement and related proxy statement/prospectus/consent solicitation, Nuvelo files annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed
by Nuvelo, Inc. at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room.
Nuvelo, Inc.s filings with the SEC are also available to the public from commercial document-retrieval services and at SECs website at http://www.sec.gov, and from Investor Relations at Nuvelo as described above.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities,
nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be
made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Nuvelo, ARCA
and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Nuvelo in connection with the merger transaction. Information regarding the special interests of these
directors and executive officers in the merger transaction will be included in the proxy statement/prospectus of described above. Additional information regarding the directors and executive officers of Nuvelo is also included in Nuvelos proxy
statement for its 2008 Annual Meeting of Stockholders which was filed with the SEC on April 23, 2008 and its Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the SEC on March 12, 2008. These
documents are available as described above.
###
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Sep 2023 to Sep 2024